search
Front > News

Drug development co Mapi Pharma raises $10m

Dr. Ehud Marom
Dr. Ehud Marom
17 Aug, 2017 16:42
שלח תגובה במיילGlobes correspondent

The financing is for a Phase III trial for the Israeli company’s lead product, Glatiramer Acetate (Copaxone) Depot, for treating multiple sclerosis.

Israeli drug development company Mapi Pharma Ltd. has completed a $10 million financing round. The money was raised from aMoon Fund, an Israeli firm investing in innovative Israeli healthcare and life science ventures, founded by Marius Nacht and Dr. Yair Schindel.

Based in Ness Ziona, Mapi Pharma develops high barrier-to-entry, high added-value lifecycle management pharmaceuticals and complex active pharmaceutical ingredients (API) and formulations.

The new financing will enable the initiation of the Phase III trial for the company’s lead product, Glatiramer Acetate (Copaxone) Depot, or GA Depot, for the treatment of multiple sclerosis (MS). Mapi Pharma recently completed a successful Phase II, open-label, two arm, multicenter, study to assess safety, tolerability, and efficacy of once-a-month, long-acting IM (intramuscular) injection of 80mg or 40mg glatiramer acetate in patients with relapsing remitting multiple sclerosis (RRMS).

Mapi Pharm chairman and CEO Ehud Marom said, "I am pleased the aMoon Fund team has decided to invest in Mapi and support our future plans. Their commitment to the company is a strong testament to the promise inherent in our clinical assets and technology platform. Their investment will enable us to advance the development of GA Depot as a potential treatment for multiple sclerosis."

aMoon Fun managing partner Dr. Yair Schindel said, "The aMoon Fund was established in order to enable exceptional Israeli healthcare companies to raise the needed funding and achieve their next significant leap. The life science industry is one of Israel’s most invaluable assets for future economic growth and Israeli investors should make sure it is not lagging behind the rest of the world due to under investments. We saw in Mapi all the necessary ingredients to build a fully-integrated Israeli-based but global pharmaceutical company, including its management, IP, technology, product pipeline and facilities. Our goal is to support Mapi’s development and production into Phase III."

Published by Globes [online], Israel business news - www.globes-online.com - on August 17, 2017

© Copyright of Globes Publisher Itonut (1983) Ltd. 2017

Dr. Ehud Marom
Dr. Ehud Marom
David Amsalem credit Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

A TSG system in tactical use credit: PR TSG signs cooperation agreement with US defense co

The agreement includes the integration of TSG's advanced technologies into sensor-based defense systems, which will be integrated into the operational systems of US defense units.

Bria CEO Yair Adato credit: Kseniia Poliak Israeli visual generative AI co Bria raises $40m

Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language.

Amnon Shashua and Aviram Ziv credit: Eyal Izhar OrCam stymied by investor dispute with Shashua

Demands by institutional investors are blocking the visual and hearing impairment device developer's recovery plan.

Work on the Green Line credit: Bar Lavi Egged wins tender to operate TA light rail Purple, Green Lines

NTA awarded the tender to Egged, which already operates the Red Line, despite government ministry opposition to one operator for the entire network.

Gabi Seroussi illustration: Gil Gibli Board chooses Seroussi as IAI chair as Erdan freezes candidacy

Israel Aerospace Industries board chose Gabi Seroussi as chair even though he did not to go through the preliminary process of the Government Companies Authority appointments review committee.

Bavli Park penthouse credit: Eyal Tagar Tel Aviv Park Bavli penthouse sells for NIS 43m

A 44th floor penthouse in one of the two towers in businessman Yitzhak Tshuva's Park Bavli project has been bought by an Israeli businessperson.

El Al aircraft credit: Yoav Yaari El Al pilots receive nearly NIS 250,000 bonus each

Thanks to the agreements signed with the unions in 2018, El Al's employees as well as senior management share in last year's success.

Pentera CEO Amitai Ratzon credit: Eyal Izhar Israeli security validation co Pentera raises $60m

Pentera's platform enables security teams to analyze complete attack paths, identify root causes, and prioritize remediation for effective risk reduction.

Tel Aviv credit: Shutterstock Supply of unsold new homes hits record

Israel's real estate market is sliding into recession with 78,000 unsold new apartments in January, the Central Bureau of Statistics reports.

D&B chairman Doron Cohen and Meitar partner Dan Geva Meitar reclaims title of Israel's biggest law firm

Meitar has first place with 537 lawyers, followed by Herzog Fox Neeman with 512 lawyers, according to the latest Dun's 100 rankings.

First International Bank of Israel CEO Eli Cohen credit: Eyal Toueg First Int'l posts top return on equity

First International Bank of Israel's return on equity in 2024 was 19%, the highest among Israel's banks.

Dina Ben Tal Ganancia credit: Guy Kushi & Yariv Fein El Al almost quintuples profit

The airline posted a net profit of $545 million for 2024, 4.7 times the profit in 2023, and an all-time high.

Gev Hadari credit: Nati Hortig Sompo Israel appoints Gev Hadari as cybersecurity head

Hadari's expertise spans penetration testing, including Red Team operations, web applications, mobile applications, OT/IOT products, and both external and internal assessments.

Attack drones credit: Shutterstock IDF issues tender for 5,000 Israeli-made attack drones

Critics of the tender say the number being procured is insufficient and thewre are security concerns about Chinese components.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018